Early response predictive of future stable MR4.5 in imatinib-treated patients with CMLAugust 29, 2021CML
CML-CP: Favorable outcomes post-TKI switch in patients intolerant/resistant to frontline 2G-TKIAugust 29, 2021CML
Superior COVID-19 outcomes in CML patients with controlled disease and on TKI therapiesAugust 29, 2021CML
Higher risk of uncontrolled BP in patients with CML receiving nilotinib vs imatinib/dasatinibAugust 29, 2021CML
Peripheral blood parameters can help identify need for BCR-ABL1 testing for CML diagnosisJuly 29, 2021CML
Prediagnosis blood cell counts predict CML development up to 5 years earlier than conventional testingJuly 29, 2021CML
